Research Article

Author for correspondence:
Marina Clare Vinaud,
E-mail: marinavinaud@gmail.com

CAMBRIDGE
UNIVERSITY PRESS

Partial inhibition of the main energetic pathways and its metabolic consequences after *in vivo* treatment with benzimidazole derivatives in experimental neurocysticercosis

Guaraciara de Andrade Picanço[1], Nayana Ferreira de Lima[1], Taynara Cristina Gomes[1], Carolina Miguel Fraga[1], Daniella de Sousa Moreira Mendes Alves[1], Rafael Castillo[2], Tatiane Luiza da Costa[3], Ruy de Souza Lino-Junior[1], Javier Ambrosio[4] and Marina Clare Vinaud[1]

[1]Tropical Pathology and Public Health Institute, Federal University of Goias, Goiania, Brazil; [2]Chemistry Faculty, National Autonomous University of Mexico, Mexico City, Mexico; [3]Clinical Hospital, Federal University of Goias, Goiania, Brazil and [4]Medicine Faculty, National Autonomous University of Mexico, Mexico City, Mexico

Abstract

Benzimidazole derivatives such as albendazole (ABZ) and mebendazole are important molecules used in helminthic treatment. Neurocysticercosis is the main cause of acquired epilepsy throughout the world and is currently treated with ABZ. New molecules have been studied in order to aid in the treatment of this neglected tropical disease, among them RCB15 and RCB20. The aim of this study was to evaluate the metabolic impact of RCB15 and RCB20 on *Taenia crassiceps* cysticerci intracranially inoculated in Balb/c mice. Thirty days after the inoculation the mice were treated with 50 mg kg^{-1} of RCB15, RCB20, ABZ or NaCl 0.9%. The euthanasia and cysticerci removal were performed 24 h after the treatment. The cysticerci were analysed through high performance liquid chromatography. After the treatments, there was an impairment in the main energetic pathways such as glycolytic pathway, homolactic fermentation or in mitochondrion energy production detected through the decrease in pyruvate, lactate, oxaloacetate, malate and fumarate concentrations. This induced the parasite to resort to alternative energetic pathways such as proteins catabolism, propionate fermentation and fatty acids oxidation. Therefore, benzimidazole derivatives are a promising alternative to ABZ use as they also reach the brain tissue and induce a metabolic stress in the cysticerci.

Introduction

The benzimidazole derivatives are important molecules used in the treatment of intestinal and tissue parasitosis. The best examples of these molecules are mebendazole, thiabendazole and albendazole (ABZ) (Bansal and Silakari, 2012; Salahuddin *et al.*, 2017). Other compounds have been synthetized from benzimidazole such as 6-chloro-5-(2,3-dichlorophenoxy)-2-(trifluoromethyl)-1*H*-benzimidazole (RCB15) and 6-chloro-5-(1-naphthyloxy)-2-(trifluoromethyl)-1H-benzimidazole (RCB20) showing important anthelminthic activity and considered promising as new molecules that may be used in the treatment of such neglected tropical diseases (Hernández-Luis *et al.*, 2010).

Neurocysticercosis (NCC) is a tissue parasitosis caused by the presence of the larval stage of *Taenia solium* in the nervous system. It is considered a neglected disease of great epidemiologic importance as it is the main cause of acquired epilepsy in endemic regions such as Latin America, Africa and Asia (Garcia *et al.*, 2014). The NCC treatment is performed through the administration of ABZ and praziquantel (PZQ) isolated or in association (Valdez *et al.*, 2002). Both ABZ and PZQ are anthelminthic drugs widely used worldwide which have induced the manifestation of some resistance reports (El-On, 2003; van den Enden, 2009; Márquez-Navarro *et al.*, 2012; Lopes *et al.*, 2014). Therefore, the search for alternative NCC treatment is of utmost importance (Hernández-Luis *et al.*, 2010).

One of the validated experimental models used for cysticercosis studies is with the intraperitoneal and intracranial inoculation of *Taenia crassiceps* cysticerci in mice, reproducing the cysticercosis host-parasite interaction (Cardona and Teale, 2002; Matos-Silva *et al.*, 2012; Leandro *et al.*, 2014; Lima *et al.*, 2019). The *T. crassiceps* experimental NCC model has been used as to contribute in the clarifying of the biochemical impact of different drugs in the metabolic pathways of the parasite (Leandro *et al.*, 2014; Silva *et al.*, 2018; Lima *et al.*, 2019).

The biochemical studies of the drugs mode of action have helped to determine their metabolic target within the parasitic cell as well as how the parasite reacts when facing a stressful environment. Such studies contribute to the development of new active compounds and improvement of the current anthelminthic drugs, i.e. development of nanosuspensions increasing the drug`s absorption by the parasitic cell as well as decreasing dosages and side-effects (Vinaud *et al.*, 2007; Picanço *et al.*, 2017; Silva *et al.*, 2018; Lima *et al.*, 2019).

The carbohydrate fermentation pathways have been previously described in cestodes (Vinaud *et al.*, 2007; Tielens *et al.*, 2010). The main end products of these energetic pathways from glucose are lactate, acetate and propionate. The fermentation processes are increased within the cell`s metabolism when there is a decrease in the availability of oxygen in the habitat or when there is an abundance of carbohydrate sources (Meganathan *et al.*, 2007). It has been reported that cestodes, such as *T. crassiceps*, are able to survive in anaerobic environments and accumulate succinate and products derived from succinate, such as propionate (Saz, 1981). The anaerobic breakdown of carbohydrates by helminths also takes in consideration the redox requirements of the environment, sources of intermediates for synthetic reactions, pH control, nitrogenous excretion, osmotic regulation, intracellular signalling and the suppression of host responses (Barrett, 1984).

Therefore, the aim of this study was to evaluate the metabolic response of *T. crassiceps* cysticerci intracranially inoculated in BALB/c mice after treatment with RCB15 and RCB20 in comparison to ABZ.

Materials and methods

The *T. crassiceps* cysticerci are maintained in the animal's facilities of the Tropical Pathology and Public Health Institute of the Federal University of Goias since 2002, as described previously (Vaz *et al.*, 1997; Fraga *et al.*, 2012).

Experimental infection and treatment

The BALB/c female mice, with 8–12 weeks old, used in this study were submitted to intracranial inoculation of initial stage *T. crassiceps* cysticerci as described previously by Matos-Silva *et al.* (2012). After a period of 30 days post-inoculation the animals received a single dose treatment of 50 mg kg^{-1} of ABZ (positive control group), 50 mg kg^{-1} of RCB15 (test group 1), 50 mg kg^{-1} of RCB20 (test group 2) or 50 μL of physiologic solution (NaCl 0.9%) (negative control group). Each experimental group was composed of five animals. All the treatments were performed orally through gavage. Twenty-four hours after the treatment the animals were euthanized. This period of time was chosen due to the half-life of ABZ which is approximately 8–12 h, ensuring the metabolic effect of the drug on the parasite. The cysticerci were carefully removed, washed with physiologic solution (NaCl 0.9%) in order to remove host cells or other interferents, and then frozen in liquid nitrogen and stored in −20 °C freezer for posterior biochemical analysis (Leandro *et al.*, 2014; Silva *et al.*, 2018; Lima *et al.*, 2019).

Biochemical analysis

The organic acids were extracted from the cysticerci according to the previous description (Fraga *et al.*, 2012). Briefly, the cysticerci were defrosted and homogenized in 500 μL of tris-HCl 0.1 M buffer supplemented with a protease inhibitor (SigmaFast protease inhibitor cocktail tablets, EDTA-free, Sigma®), pH 7.6. The extract obtained was centrifuged at 15 652 g (10 000 rpm) per 10 min at 4 °C and then the organic acids present in the vesicular fluid were extracted through an ionic exchange solid phase extraction column (Bond Elut® Agilent®). The chromatographic analysis was performed through an exclusion column BIORAD-Aminex HPX-87H®. The eluent used was sulfuric acid 5 mM, flow 0.6 mL min^{-1}, spectrophotometric reading of 210 nm.

The results were analysed through the Star Chromatography Workstation software (Agilent®), previously calibrated for the following organic acids identification: pyruvate and lactate (glycolytic pathway), oxaloacetate, citrate, α-ketoglutarate, succinate, fumarate and malate (tricarboxylic acid cycle), fatty acids oxidation (acetate, acetoacetate, β-hydroxybutyrate).

Dosages of glucose, lactate dehydrogenase (LDH), urea and creatinine were performed through an Architec C8000 Plus device with commercial kits (Doles®) that employed the enzymatic method for quantification.

Statistical analysis

All experiments were independently repeated five times. As the amount of cysticerci removed from each mouse is not standardized, the cysticerci were weighted and the values detected by HPLC and spectrophotometry were adjusted per gram of cysticerci. The statistical analysis was performed with the adjusted values from the biochemical analysis of the cysticerci through the Sigma Stat 2.3 software. The descriptive analysis was performed to determine the normal distribution and homogenous variation as well as mean and standard deviation. As the values presented normal distribution, the analysis of variation test was performed. The differences were considered significant when $P < 0.05$.

Results

The analyses performed in this study allowed the determination of the metabolic pathways used by *T. crassiceps* cysticerci intracranially inoculated in BALB/c mice after the *in vivo* treatment with benzimidazole derivatives. This study focused on the cytoplasmatic energetic pathways such as the glycolytic and proteins catabolism, and on the mitochondrion energetic alternative pathway such as the fatty acids oxidation.

All treatments influenced the glycolytic and cytoplasmic anaerobic energetic pathway (Table 1). The ABZ and RCB20 induced a similar significant decrease in the concentrations of pyruvate (five and four times, respectively) and lactate (two times for both treatments) when compared to the control group. While the RCB15 treatment induced a greater decrease in this pathway, i.e. pyruvate was not detected and lactate was 15 times decreased.

The RCB15 treatment induced a decrease in all mitochondrion organic acids related to the tricarboxylic acid cycle such as citrate (10 times), non-detection of α-ketoglutarate, succinate, malate and oxaloacetate (Tables 2 and 3).

After the RCB15 treatment, the parasite produced energy through the catabolism of proteins (fumarate, urea and creatinine detections), fatty acids oxidation (β-hydroxybutyrate detection) and propionate anaerobic fermentation (Tables 2 and 3).

The RCB20 and ABZ treatment induced similar effects on the metabolic pathways such as a decrease in tricarboxylic acid cycle intermediates (oxaloacetate, malate and fumarate) and increase in the fatty acid's oxidation (β-hydroxybutyrate) (Tables 2 and 3).

The RCB20 treatment also induced the propionate anaerobic fermentation which was not observed in the ABZ treated group or in the control group (Table 3).

It was not possible to detect in all analysed samples α-ketoglutarate, succinate nor acetate.

Figure 1 shows the molecular structures of ABZ, RCB15 and RCB20 and the main metabolic impact on the experimental NCC treatment.

Discussion

This study evaluated the metabolic alterations observed in *T. crassiceps* cysticerci intracranially inoculated in BALB/c mice after the *in vivo* treatment with benzimidazole derivatives, RCB15, RCB20 and ABZ.

The main mode of action of the benzimidazole derivatives is to impair the polymerization of tubulins (α and β) into microtubules

Table 1. Concentrations (mean ± standard error) of glucose, pyruvate, lactate dehydrogenase (LDH) and lactate per gram of cysticerci detected in *Taenia crassiceps* cysticerci intracranially inoculated in BALB/c mice after treatment with albendazole, RCB15 or RCB20

	Control	ABZ	RCB15	RCB20
Glucose (mg dL^{-1})	54.14 ± 9.42	41.19 ± 5.21	39.84 ± 1.53	54.25 ± 7.95
Pyruvate (μM)	155.60 ± 82.40	**28.79 ± 7.29***	ND	**38.44 ± 9.17***
LDH (UI L^{-1})	266.52 ± 110.84	**96.52 ± 7.75***	239.02 ± 9.18[a]	280.27 ± 37.95[a]
Lactate (μM)	6765.81 ± 2471.65	**3087.28 ± 692.10***	**427.62 ± 296.48*[a]**	**3366.41 ± 863.78*[b]**

ND, non-detected, control group: treatment with NaCl 0.9%; ABZ, albendazole treated group; RCB15, 6-chloro-5-(2,3-dichlorophenoxy)-2-(trifluoromethyl)-1*H*-benzimidazole treated group; RCB20, 6-chloro-5-(1-naphthyloxy)-2-(trifluoromethyl)-1H-benzimidazole treated group. The bold marking alongside with * indicates the statistical significant difference.
*$P < 0.05$ when compared to the control group; a: $P < 0.05$ when compared to the concentrations detected in the positive control group (albendazole treated group); b: $P < 0.05$ when compared to the concentrations detected in the RCB15 treated group.

Table 2. Concentrations (mean ± standard error) of citrate, malate, oxaloacetate and fumarate detected per gram of cysticerci in *Taenia crassiceps* cysticerci intracranially inoculated in BALB/c mice after treatment with albendazole, RCB15 or RCB20

	Control	ABZ	RCB15	RCB20
Citrate (μM)	1487.00 ± 303.09	1385.78 ± 148.22	**160.33 ± 42.42*[a]**	1074.07 ± 376.15
Oxaloacetate (μM)	183.78 ± 148.22	162.77 ± 11.21	ND	**127.94 ± 51.38***
Malate (μM)	1167.72 ± 86.03	**894.65 ± 228.25***	ND	**827.25 ± 109.82***
Fumarate (μM)	251.79 ± 49.58	205.84 ± 63.41	**48.05 ± 11.66*[a]**	**99.31 ± 27.09*[ab]**

ND, non-detected, control group: treatment with NaCl 0.9%; ABZ, albendazole treated group; RCB15, 6-chloro-5-(2,3-dichlorophenoxy)-2-(trifluoromethyl)-1*H*-benzimidazole treated group; RCB20, 6-chloro-5-(1-naphthyloxy)-2-(trifluoromethyl)-1H-benzimidazole treated group. The bold marking alongside with * indicates the statistical significant difference.
*$P < 0.05$ when compared to the control group; a: $P < 0.05$ when compared to the concentrations detected in the positive control group (albendazole treated group); b: $P < 0.05$ when compared to the concentrations detected in the RCB15 treated group.

Table 3. Concentrations (mean ± standard error) of urea, creatinine, propionate and β-hydroxybutyrate detected per gram of cysticerci in *Taenia crassiceps* cysticerci intracranially inoculated in BALB/c mice after treatment with albendazole, RCB15 or RCB20

	Control	ABZ	RCB15	RCB20
Urea (mg dL^{-1})	26.67 ± 4.62	**16.84 ± 0.80***	**31.87 ± 1.22*[a]**	**28.84 ± 6.64[ab]**
Creatinine (mg dL^{-1})	1.13 ± 0.28	0.64 ± 0.05	**1.59 ± 0.06[a]**	**1.49 ± 0.37[a]**
Propionate (μM)	ND	ND	411.27 ± 180.39	1087.36 ± 733.71
β-hydroxybutyrate (μM)	ND	3429.76 ± 665.44	**1309.22 ± 571.53[a]**	**3403.46 ± 352.00[b]**

ND, non-detected, control group: treatment with NaCl 0.9%; ABZ, albendazole treated group; RCB15, 6-chloro-5-(2,3-dichlorophenoxy)-2-(trifluoromethyl)-1*H*-benzimidazole treated group; RCB20, 6-chloro-5-(1-naphthyloxy)-2-(trifluoromethyl)-1H-benzimidazole treated group. The bold marking alongside with * indicates the statistical significant difference.
*$P < 0.05$ when compared to the control group; a: $P < 0.05$ when compared to the concentrations detected in the positive control group (albendazole treated group); b: $P < 0.05$ when compared to the concentrations detected in the RCB15 treated group.

(Martin, 1997). Microtubules are the most common component of the cytoskeleton and are involved in several intracellular processes such as mitosis, ciliary and flagellar motility, transport through vesicles and organelles (Nogales, 2000). The impairment of such structures alters the tegument integrity of cestodes (Marquez-Navarro *et al*., 2013) and metabolically leads to difficulties in glucose uptake and induces the increase of alternative energetic pathways such as anaerobic fermentative pathways, proteins catabolism, fatty acids oxidation and gluconeogenesis (Martin, 1997; Vinaud *et al*., 2009; Fraga *et al*., 2017; Picanço *et al*., 2017; Vinaud and Lino Junior, 2017; Lima *et al*., 2019).

In spite of the same concentrations of glucose detected in all groups, the treatments induced a significant decrease in the glycolytic and homolactic fermentation pathways, observed through the smaller amounts of pyruvate and lactate concentrations detected. The glucose uptake impairment described previously as a mode of action of benzimidazole derivatives (Martin, 1997; Marquez-Navarro, 2013) was not observed in our results. However, the significant decrease in pyruvate concentrations may have happened due to the inhibition of one of the glycolytic enzymes such as glucose-6-phosphate dehydrogenase which has been reported as one of the metabolic effects of benzimidazole derivatives (Sarwal *et al*., 1989). These data may also be explained by the repressing effect of benzimidazole derivatives on the Vmax of the glycolytic enzymes and also on their substrate affinity (Jasra *et al*., 1990).

The malate dehydrogenase complex is considered one of the most important within the parasite`s energetic pathways as it is responsible for the malate syntheses from oxaloacetate in the cytoplasm as well as in the mitochondrion. The inhibition of this enzyme by benzimidazole derivatives leads to a blockage of the glycolytic pathways and to a significant decrease in the parasite energetic reserve (Tejada *et al*., 1987). It is interesting to highlight that in our results was possible to observe a significant decrease in malate concentrations after all treatments. Also, after the RCB15 treatment no pyruvate, oxaloacetate nor malate were detected. These data show that this particular benzimidazole derivative presents a greater metabolic effect than the other two tested in this study.

The enzymatic inhibition as a mode of action of ABZ derivatives has been reported previously. The malate dehydrogenase both cytoplasmic and mitochondrial are inhibited by ABZ (Tejada *et al*., 1987) leading the decreases of malate concentrations and affecting the glycolytic and tricarboxylic acid cycle pathways. The fumarate reductase enzyme is inhibited by thiabendazole (Prichard, 1970) impairing the mitochondrial pathways. These reports show that benzimidazole derivatives may present

Fig. 1. Molecular structures of albendazole; RCB15: 6-chloro-5-(2,3-dichlorophenoxy)-2-(trifluoromethyl)-1*H*-benzimidazole; RCB20: 6-chloro-5-(1-naphthyloxy)-2-(trifluoromethyl)-1H-benzimidazole used in the *in vivo* treatment of experimental neurocysticercosis with *Taenia crassiceps* cysticerci. On the right the main metabolic impact of the drugs, red arrows indicate a decrease in the metabolite after treatment, blue arrows indicate an increase in the metabolite after treatment.

different sites of inhibition regarding the varied enzymes of the parasites. This was probably observed in our results regarding the LDH activity when the parasite was exposed to ABZ, RCB15 and RCB20. The first drug partially inhibited the enzyme as reported previously (Veerakumari and Munuswamy, 2000), while the other two derivatives presented no effect in its activity.

On the other hand, RCB15 treatment induced a significant decrease in lactate concentrations. This probably occurred due to the non-detection of pyruvate which is the precursor of lactate. It is possible that this derivative has a greater inhibition effect on the pyruvate kinase enzyme leading to a decrease in pyruvate production and, therefore, impacting the homolactic fermentation. The inhibition of pyruvate kinase by benzimidazole derivatives has been described previously by Cornish and Bryant (1976).

At this point it is interesting to observe that the parasite after the benzimidazole treatments could not perform the main energetic pathway, i.e. the glycolysis and presented an impairment in the tricarboxylic acid (TCA) cycle with significant decreases in the concentrations of oxaloacetate, malate and fumarate as well as the non-detection of α-ketoglutarate and succinate. In other words, the TCA cycle was not functioning nor the fumarate reductase pathway. These two important energetic pathways have been reported previously in *T. crassiceps* cysticerci intracranially inoculated in mice (Leandro *et al.*, 2014).

In order to ensure survival and a minimum energetic production, the parasites intensified other biochemical pathways: the proteins catabolism, fatty acids oxidation and propionate fermentation. These pathways have already been described in *T. crassiceps* cysticerci inoculated both intracranially and intraperitoneally (Leandro *et al.*, 2014; Fraga *et al.*, 2016; Nasareth *et al.*, 2017; Lima *et al.*, 2019).

Regarding the protein's catabolism, the ABZ treatment did not influence this energetic pathway. While both benzimidazole derivatives, RCB15 and RCB20, showed a slight increase in the urea concentrations while there was a decrease in the fumarate ones. Again, RCB15 showed greater influence in this pathway than RCB20. These results are in accordance with the previously described effect of benzimidazole derivatives on *T. crassiceps* cysticerci (Fraga *et al.*, 2016; Picanço *et al.*, 2017). The proteins catabolism plays an important role in several physiologic processes such as growth, differentiation and reproduction within the host (Zhang *et al.*, 2018). Therefore, its impairment as a result of benzimidazole derivative exposures represents an important impact on their survival in such a significant site, the central nervous system.

On the other hand, after such important metabolic decreases, the parasite ensured survival at short term by increasing significantly the fatty acids oxidation and the propionate fermentation as energy production pathways. These two metabolic pathways were able to maintain the parasite`s survival within the analysed period of time. The increase in these alternative pathways after drugs exposure is in accordance with the previous description of the metabolic elasticity of *T. crassiceps* cysticerci (Vinaud *et al.*, 2009; Fraga *et al.*, 2017; Picanço *et al.*, 2017).

The metabolic studies of *T. crassiceps* responses to benzimidazole drugs show that this parasite tends to resort to fermentative pathways such as the production of propionate from lactate or from succinate (Fraga *et al.*, 2017; Picanço *et al.*, 2017). It is important to highlight that when there is no interference in the glycolytic pathway, homolactic fermentation or in mitochondrion energy production the propionate fermentation pathway is not activated or, if present, found in small concentration, as detected in our control group. But when there is some kind of impairment of the main energetic pathways it is activated and becomes the main energetic source. These data show how this pathway is important as a survival escape used by the parasite.

When comparing both benzimidazole derivatives, RCB15 and RCB20, regarding the treatment of experimental NCC, it was possible to observe that the first one presented greater metabolic impact on the cysticerci regarding the homolactic fermentation, citric acid cycle and protein`s catabolism. Hypothetically, this probably was observed due to a greater impact on tubulins formation, since drugs of the benzimidazole group are known to affect both α and β microtubules polymerization (Martin, 1997; Aguayo-Ortiz *et al.*, 2013). Further studies are needed in order to demonstrate the precise effect of each benzimidazole derivative in the cytoskeleton proteins and tegumental structures.

In conclusion, the benzimidazole derivatives are able to influence the energetic metabolism of *T. crassiceps* cysticerci forcing the parasite to resort to alternative energetic pathways in order to survive. Both RCB15 and RCB20 showed promising anthelminthic activity although the first one was found to present a more significant impact on the parasite`s metabolism.

Conflict of interest. None.

Ethical standards. This study obeyed the ethical principles in animal experimentation stipulated by the Brazilian Society of Laboratory Animals Science (SBCAL) and was approved by the Ethics Committee in Animal Use of the Federal University of Goias (CEUA/UFG), protocol number 049/17.

References

Aguayo-Ortiz R, Méndez-Lucio O, Romo-Mancillas A, Castillo R, Yépez-Mulia L, Medina-Franco JL and Hernández-Campos A (2013) Molecular basis for benzimidazole resistance from a novel β-tubulin binding site model. *Journal of Molecular Graphics and Modelling* **45**, 26–37.

Bansal Y and Silakari O (2012) The therapeutic journey of benzimidazoles: a review. *Bioorganic & Medicinal Chemistry* **20**, 6208–6236.

Barrett J (1984) The anaerobic end-products of helminths. *Parasitology* **88**(Pt 1), 179–198.

Cardona AE and Teale JM (2002) Gamma/delta T cell-deficient mice exhibit reduced disease severity and decreased inflammatory response in the brain in murine neurocysticercosis. *The Journal of Immunology* **169**, 3163–3171. https://doi.org/10.4049/jimmunol.169.6.3163.

Cornish RA and Bryant C (1976) Changes in energy metabolism due to anthelmintics in *Fasciola hepatica* maintained in vitro. *International Journal of Parasitology* **6**, 393–398.

El-On J (2003) Benzimidazole treatment of cystic echinococcosis. *Acta Tropica* **85**, 243–252. https://doi.org/10.1016/S0001-706X(02)00217-6.

Fraga MC, Costa TL, Bezerra JCB, Lino Junior RS and Vinaud MC (2012) *Taenia crassiceps*: host treatment alters glycolysis and tricarboxilic acid cycle in cysticerci. *Experimental Parasitology* **130**, 146–151.

Fraga CM, Costa TL, Castro AM, Reynoso-Ducoing O, Ambrosio J, Hernández Campos A, Castillo R and Vinaud MC (2016) Alternative energy production pathways in *Taenia crassiceps* cysticerci in vitro exposed to a benzimidazole derivative (RCB20). *Parasitology* **143**, 488–493.

Fraga CM, Costa TL, Castro AM, Reynoso-Ducoing O, Ambrosio J, Hernández-Campos A, Castillo R and Vinaud MC (2017) A benzimidazole derivative (RCB20) in vitro induces an activation of energetic pathways on *Taenia crassiceps* (ORF strain) cysticerci. *Experimental Parasitology* **172**, 12–17.

Garcia HH, Nash TE and Del Bruto OH (2014) Clinical symptoms, diagnosis, and treatment of neurocysticercosis. *Lancet Neurology* **13**, 1202–1215.

Hernández-Luis F, Hernández-Campos A, Castillo R, Navarret-Vázquez G, Soria-Arteche O, Hernández-Hernández M and Yépez-Mulia L (2010) Synthesis and biological activity of 2-(trifluoromethyl)-1H-benzimidazole derivatives against some protozoa and *Trichinella spiralis*. *European Journal of Medicinal Chemistry* **45**, 3135–3141. https://doi.org/10.1016/j.ejmech.2010.03.050.

Jasra N, Sanyal SN and Khera S (1990) Effect of thiabendazole and fenbendazole on glucose uptake and carbohydrate metabolism in *Trichuris globulosa*. *Veterinary Parasitology* **35**, 201–209. https://doi.org/10.1016/0304-4017(90)90055-G.

Leandro LA, Fraga CM, Lino Junior RS and Vinaud MC (2014) Partial reverse of the TCA cycle is enhanced in *Taenia crassiceps* experimental neurocysticercosis after *in vivo* treatment with anthelminthic drugs. *Parasitology Research* **113**, 1313–1317.

Lima NF, Picanço GA, Alves DSMM, Silva LD, Isac E, Costa TL, Lino Junior RS and Vinaud MC (2019) Oral nitazoxanide treatment of experimental neurocysticercosis induces gluconeogenesis in *Taenia crassiceps* cysticerci. *Acta Tropica* **190**, 361–364.

Lopes WDZ, Cruz BC, Soares VE, Nunes JLN, Teixeira WFP, Maciel WG, Buzzulini C, Pereira JCM, Felippelli G, Soccol VT, Oliveira GP and Costa AJ (2014) Historic of therapeutic efficacy of albendazole sulphoxide administered in different routes, dosages and treatment schemes, against *Taenia saginata* cysticercus in cattle experimentally infected. *Experimental Parasitology* **137**, 14–20.

Márquez-Navarro A, Cornejo-Coria MC, Cebada-López F, Sánchez-Manzano RM, Diaz-Chiguer DL and Nogueda-Torres B (2012) *Taenia saginata*: failure treatment in a child with 5-year long-lasting infection. *Gastroenterology Nursing* **35**, 125–127.

Marquez-Navarro A, Perez-Reyes A, Zepeda-Rodriguez A, Reynoso-Ducoing O, Hernandez-Campos A, Hernandez-Luiz F, Castillo R, Yepez-Mulia L and Ambrosio JR (2013) RCB20, an experimental benzimidazole derivative, affects tubulin expression and induces gross anatomical changes in *Taenia crassiceps* cysticerci. *Parasitology Research* **112**, 2215–2226.

Martin RJ (1997) Modes of action of anthelmintic drugs. *The Veterinary Journal* **154**, 11–34. https://doi.org/10.1016/S1090-0233(05)80005-X.

Matos-Silva H, Reciputti BP, Paula EC, Oliveira AL, Moura VBL, Vinaud MC, Oliveira MAP and Lino-Júnior RS (2012) Experimental encephalitis caused by *Taenia crassiceps* cysticerci in mice. *Arquivos de Neuropsiquiatria* **70**, 287–292. http://dx.doi.org/10.1590/S0004-282X2012005000010.

Meganathan R, Ranganathan Y and Reddy CA (2007) Carbohydrate fermentations. In Reddy CA, Beveridge TJ, Breznak JA, Marzluff GA and Schmidt TM (eds), *Methods for General and Molecular Microbiology*. Washington, DC: American Society for Microbiology Press, pp. 558–585.

Nasareth JM, Fraga CM, Lima NF, Picanço GA, Costa TL, Lino-Junior RS and Vinaud MC (2017) *In vivo* treatment with nitazoxanide induces anaerobic metabolism in experimental intraperitoneal cysticercosis. *Parasitology Research* **116**, 3037–3041.

Nogales E (2000) Structural insights into microtubule function. *Annual Review of Biochemistry* **69**, 277–302. https://doi.org/10.1146/annurev.biochem.69.1.277.

Picanço GA, Lima NF, Fraga CM, Costa TL, Isac E, Ambrosio J, Castillo R and Vinaud MC (2017) A benzimidazole derivative (RCB15) *in vitro* induces the alternative energetic metabolism and glycolysis in *Taenia crassiceps* cysticerci. *Acta Tropica* **176**, 288–292.

Prichard RK (1970) Mode of action of the anthelminthic thiabendazole in *Haemonchus contortus*. *Nature* **228**, 684–685.

Salahuddin, Shaharyar M and Mazumder A (2017) Benzimidazoles: a biologically active compounds. Arabian Journal of Chemistry **10**, S157–S173. https://doi.org/10.1016/j.arabjc.2012.07.017.

Sarwal R, Sanyal SN and Khera S (1989) In vitro effect of benzimidazole drugs on the enzymes of lipid metabolism in *Trichuris globulosa*. *The Journal of Parasitology* **75**, 808.

Saz HJ (1981) Energy metabolisms of parasitic helminths: adaptations to parasitism. *Annual Review of Physiology* **43**, 323–341. https://doi.org/10.1146/annurev.ph.43.030181.001543.

Silva LD, Lima NF, Arrua EC, Salomon CJ and Vinaud MC (2018) *In vivo* treatment of experimental neurocysticercosis with praziquantel nanosuspensions-a metabolic approach. *Drug Delivery and Translational Research* **8**, 1265–1273.

Tejada P, Sanchez-Moreno M, Monteoliva M and Gomez-Banqueri H (1987) Inhibition of malate dehydrogenase enzymes by benzimidazole anthelmintics. *Veterinary Parasitology* **24**, 269–274. https://doi.org/10.1016/0304-4017(87)90048-3.

Tielens AGM, van Grinsvenm KWA, Henze K, van Hellemond JJ and Martin W (2010) Acetate formation in the energy metabolism of parasitic helminths and protists. *International Journal for Parasitology* **40**, 387–397.

van den Enden E (2009) Pharmacotherapy of helminth infection. *Expert Opinion on Pharmacotherapy* **10**, 435–451.

Valdez J, Cedillo R, Hernandez-Campos A, Yepez L, Hernández-Luis F, Navarrete-Vázquez G, Tapia A, Cortés R, Hernández M and Castillo R (2002) Synthesis and antiparasitic activity of 1H-benzimidazole derivatives. *Bioorganic & Medicinal Chemistry Letters* **12**, 2221–2224. https://doi.org/10.1016/S0960-894X(02)00346-3.

Vaz AJ, Nunes CM, Piazza RM, Livramento JA, Da Silva MV and Nakamura PM (1997) Immunoblot with cerebrospinal fluid from patients with neurocysticercosis using antigen from cysticerci of *Taenia solium* and *Taenia crassiceps*. *The American Journal of Tropical Medicine and Hygiene* **57**, 354–357.

Veerakumari L and Munuswamy N (2000) *In vitro* effect of some anthelmintics on lactate dehydrogenase activity of *Cotylophoron cotylophorum* (Digenea: Paramphistomidae). *Veterinary Parasitology* **91**, 129–140.

Vinaud MC and Lino Junior RS (2017) Mode of action of the main antiparasitic drugs. *Journal of Tropical Pathology* **46**, 121–133.

Vinaud MC, Lino Junior RS and Bezerra JCB (2007) *Taenia crassiceps* organic acids detected in cysticerci. *Experimental Parasitology* **116**, 335–339.

Vinaud MC, Ferreira CS, Lino Junior RS and Bezerra JCB (2009) *Taenia crassiceps*: fatty acids oxidation and alternative energy source in in vitro cysticerci exposed to anthelminthic drugs. *Experimental Parasitology* **122**, 208–211.

Zhang S, Cai X, Luo X, Wang S, Guo A, Hou J and Wu R (2018) Molecular cloning and characterization of leucine aminopeptidase gene from *Taenia pisiformis*. *Experimental Parasitology* **186**, 1–9.